Friday, July 10, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “nimotuzumab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 13
Total indexed 20,548
Sponsors 1,771

Quick answer

Showing 13 pipeline programs matching "nimotuzumab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

13 results for “nimotuzumab” Back to intelligence hub

Search results

  1. AFMMUChina

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial
  2. Nimotuzumab

    Praxis Precision Medicines

    Pancreatic Cancer, Advanced or Metastatic

    phase 3 small molecule completed

    1 trial
  3. Nimotuzumab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial
  4. HRS-4642+AG+Nimotuzumab

    Zhejiang University

    Borderline Resectable Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial
  5. Nimotuzumab

    Chinese University of Hong Kong

    Esophageal Cancer

    phase 2 small molecule completed

    1 trial
  6. Nimotuzumab

    The First People's Hospital of Lianyungang

    Esophageal Neoplasms

    phase 2 small molecule active

    1 trial
  7. Nimotuzumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial
  8. Nimotuzumab + SHR-1210

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial
  9. Nimotuzumab combined with chemoradiotherapy

    The First People's Hospital of Lianyungang

    Pancreatic Cancer Non-resectable

    phase 2 small molecule active

    1 trial
  10. SBRT combined with Nimotuzumab followed by Tislelizumab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Cancinoma (NPC)

    phase 2 small molecule active

    1 trial
  11. cisplatin and 5-Fu combined with nimotuzumab

    The First People's Hospital of Lianyungang

    Stage IV Nasopharyngeal Carcinoma

    phase 2 small molecule completed

    1 trial
  12. Nimotuzumab

    Biotech Pharmaceutical Co.,

    Solid Tumors

    phase 1 small molecule active

    1 trial
  13. Nimotuzumab and chemotherapy

    Biotech Pharmaceutical Co.,

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.